Hyperosmolarity enhanced susceptibility to renal tubular fibrosis by modulating catabolism of type I transforming growth factor-β receptors

Journal of Cellular Biochemistry

Volumn 109, Issue 4, 2010, Pages 663-671

  Chiang, Tai An ^a   Yang, Yu Lin ^a   Yang, Ya Ying ^a   Hu, Min Hsiu ^a   Wu, Pei Fen ^b   Liu, Shu Fen ^c   Huang, Ruay Ming ^d   Liao, Tung Nan ^a   Hung, Chien Ya ^a   Hung, Tsung Jen ^d   Lee, Tao Chen ^e  

^a CHUNG HWA UNIVERSITY OF MEDICAL TECHNOLOGY   (Taiwan)

^b TAJEN UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d Chest Hospital   (Taiwan)

^e CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Half life; Hyperosmolarity; Receptors; SMAD; SMURF; TGF

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; COMPLEMENTARY DNA; CYCLOHEXIMIDE; FIBRONECTIN; GLUCOSE; MANNITOL; PROTEASOME INHIBITOR; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA1; TYROSINE;

ANIMAL CELL; ARTICLE; CATABOLISM; CELL STRAIN; CELL TYPE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE PREDISPOSITION; DOSE TIME EFFECT RELATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROGENESIS; FLOW CYTOMETRY; HALF LIFE TIME; HYPEROSMOLARITY; IMMUNOBLOTTING; KIDNEY DISEASE; KIDNEY DISTAL TUBULE; KIDNEY FIBROSIS; KIDNEY TUBULE DISORDER; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; UBIQUITINATION;

ANIMALS; CELL LINE; DISEASE SUSCEPTIBILITY; DOGS; FIBROSIS; KIDNEY DISEASES; KIDNEY TUBULES; MANNITOL; OSMOLAR CONCENTRATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN STABILITY; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SMAD7 PROTEIN; UBIQUITINATION;

EID: 77749310001     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22444     Document Type: Article

References (26)

1. Benigni A, Zoja C, Corna D, Zatelli C, Conti S, Campana M, Gagliardini E, Rottoli D, Zanchi C, Abbate M, Ledbetter S, Remuzzi G. 2003. Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. 1. J Am Soc Nephrol 14(7):1816-1824.
2. Chuang LY, Guh JY, Liu SF, Hung MY, Liao TN, Chiang TA, Huang JS, Huang YL, Lin CF, Yang YL. 2003. Regulation of type II transforming-growthfactor-beta receptors by protein kinase C iota. Biochem J 375(Pt 2):385-393.
3. Dave GS, Kalia K. 2007. Hyperglycemia induced oxidative stress in type-1 and type-2 diabetic patients with and without nephropathy. Cell Mol Biol (Noisy-le-grand) 53(5):68-78.
4. Fu K, Corbley MJ, Sun L, Friedman JE, Shan F, Papadatos JL, Costa D, Lutterodt F, Sweigard H, Bowes S, Choi M, Boriack-Sjodin PA, Arduini RM, Sun D, Newman MN, Zhang X, Mead JN, Chuaqui CE, Cheung HK, Zhang X, Cornebise M, Carter MB, Josiah S, Singh J, Lee WC, Gill A, Ling LE. 2008. SM16, an orally active TGF{beta} type I receptor inhibitor prevents myofi-broblast induction and vascular fibrosis in the rat carotid injury model. Arterioscler Thromb Vasc Biol. 28(4):665-671.
5. Goldfarb S, Ziyadeh FN. 2001. TGF-beta: A crucial component of the pathogenesis of diabetic nephropathy. Trans Am Clin Climatol Assoc 112:27-32, discussion 33.
6. Guh JY, Yang ML, Yang YL, Chang CC, Chuang LY. 1996. Captopril reverses high-glucose-induced growth effects on LLC-PK1 cells partly by decreasing transforming growth factor-beta receptor protein expressions. J Am Soc Nephrol 7(8):1207-1215.
7. Guterman A, Glickman MH. 2004. Deubiquitinating enzymes are IN/(trinsic to proteasome function). Curr Protein Pept Sci 5:201-211.
8. Hodgkinson AD, Bartlett T, Oates PJ, Millward BA, Demaine AG. 2003. The response of antioxidant genes to hyperglycemia is abnormal in patients with type 1 diabetes and diabetic nephropathy. Diabetes 52(3):846-851.
9. Hoffman BB, Sharma K, Ziyadeh FN. 1998. Potential role of TGF-beta in diabetic nephropathy. Miner Electrolyte Metab 24(2-3):190-196 (review).
10. Itoh S, ten Dijke P. 2007. Negative regulation of TGF-beta receptor/Smad signal transduction. Curr Opin Cell Biol 19(2):176-184 [Epub February 20, 2007, review].
11. Kavsak P, Rasmussen RK, Causing CG, Bonni S, Zhu H, Thomsen GH, Wrana JL. 2000. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell 6(6):1365-1375.
12. Küper C, Bartels H, Fraek ML, Beck FX, Neuhofer W. 2007. Ectodomain shedding of pro-TGF-alpha is required for COX-2 induction and cell survival in renal medullary cells exposed to osmotic stress. Am J Physiol Cell Physiol 293(6):C1971-C1982.
13. Lawler S, Feng XH, Chen RH, Maruoka EM, Turck CW, Griswold-Prenner I, Derynck R. 1997. The type II transforming growth factor-beta receptor autophosphorylates not only on serine and threonine but also on tyrosine residues. J Biol Chem 272(23):14850-14859.
14. Mehra A, Wrana JL. 2002. TGF-beta and the Smad signal transduction pathway. Biochem Cell Biol 80(5):605-622 (review).
15. Moustakas A, Souchelnytskyi S, Heldin CH. 2001. Smad regulation in TGFbeta signal transduction. J Cell Sci 114(Pt 24):4359-4369 (review).
16. Ng DP, Warram JH, Krolewski AS. 2003. TGF-beta 1 as a genetic susceptibility locus for advanced diabetic nephropathy in type 1 diabetes mellitus: An investigation of multiple known DNA sequence variants. AmJ Kidney Dis 41(1):22-28.
17. Pantsulaia T. 2006. Role of TGF-beta in pathogenesis of diabetic nephropathy. Georgian Med News 131:13-18 (review). PMID: 16575121.
18. Petersen M, Thorikay M, Deckers M, van Dinther M, Grygielko ET, Gellibert F, de Gouville AC, Huet S, Ten Dijke P, Laping NJ. 2007. Oral administration of GW788388, an inhibitor of TGF-beta type I and II receptor kinases, decreases renal fibrosis. Kidney Int 73(6):705-715.
19. Schrijvers BF, De Vriese AS. 2007. Novel insights in the treatment of diabetic nephropathy. Acta Clin Belg 62(5):278-290.
20. Tamaki K, Okuda S. 2003. Role of TGF-beta in the progression of renal fibrosis. Contrib Nephrol 139:44-65 (review). PMID: 12854318.
21. Yamaguchi T, Kurisaki A, Yamakawa N, Minakuchi K, Sugino H. 2006. FKBP12 functions as an adaptor of the Smad7-Smurf1 complex on activin type I receptor. J Mol Endocrinol 36:569-579.
22. Yang ML, Guh JY, Lai YH, Yang YL, Chang CC, Tsai JH, Chuang LY. 1997a. Effects of high glucose culture on EGF effects and EGF receptors in the LLCPK1 cells. Am J Nephrol 17(2):193-198.
23. Yang ML, Guh JY, Yang YL, Chang CC, Chuang LY. 1997b. Captopril reverses high glucose-induced effects on LLC-PK1 cells partly by enhancing facilitative glucose transporter messenger RNA expressions. Biochem Mol Biol Int 41(3):511-519.
24. Yang YL, Guh JY, Yang ML, Lai YH, Tsai JH, Hung WC, Chang CC, Chuang LY. 1998. Interaction between high glucose and TGF-beta in cell cycle protein regulations in MDCK cells. J Am Soc Nephrol 9(2):182-193.
25. Zhang J. 2004. A new trick to tune down TGF-beta signal. Cell Res 14(5):439-440.
26. Zhu H, Kavsak P, Abdollah S, Wrana JL, Thomsen GH. 1999. A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. Nature 400(6745):687-693.